Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis.
Mai AS, Lee ARYB, Tay RYK, Shapiro L, Thakkar A, Halmos B, Grinshpun A, Herishanu Y, Benjamini O, Tadmor T, Shroff RT, LaFleur BJ, Bhattacharya D, Peng S, Tey J, Lee SC, Chai LYA, Soon YY, Sundar R, Lee MX. Mai AS, et al. Among authors: herishanu y. Eur J Cancer. 2022 Sep;172:65-75. doi: 10.1016/j.ejca.2022.05.029. Epub 2022 Jun 3. Eur J Cancer. 2022. PMID: 35753213 Free PMC article. Review.
Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.
Tadmor T, Shvidel L, Aviv A, Ruchlemer R, Bairey O, Yuklea M, Herishanu Y, Braester A, Rahimi-Levene N, Vernea F, Ben-Ezra J, Bejar J, Polliack A; Israeli CLL Study Group. Tadmor T, et al. Among authors: herishanu y. Cancer. 2013 May 15;119(10):1853-9. doi: 10.1002/cncr.27930. Epub 2013 Feb 19. Cancer. 2013. PMID: 23423815 Free article.
Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group.
Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, Klepfish A, Ruchlemer R, Berrebi A, Polliack A; Israeli CLL Study Group. Shvidel L, et al. Among authors: herishanu y. Eur J Haematol. 2014 Jul;93(1):29-33. doi: 10.1111/ejh.12290. Epub 2014 Mar 12. Eur J Haematol. 2014. PMID: 24547751
Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.
Tadmor T, Shvidel L, Bairey O, Goldschmidt N, Ruchlemer R, Fineman R, Rahimi-Levene N, Herishanu Y, Yuklea M, Arad A, Aviv A, Polliack A; Israeli CLL Study Group. Tadmor T, et al. Among authors: herishanu y. Am J Hematol. 2014 Nov;89(11):E218-22. doi: 10.1002/ajh.23826. Epub 2014 Sep 2. Am J Hematol. 2014. PMID: 25110869 Free article.
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.
Gentile M, Zirlik K, Ciolli S, Mauro FR, Di Renzo N, Mastrullo L, Angrilli F, Molica S, Tripepi G, Giordano A, Di Raimondo F, Selleri C, Coscia M, Musso M, Orsucci L, Mannina D, Rago A, Giannotta A, Ferrara F, Herishanu Y, Shvidel L, Tadmor T, Scortechini I, Ilariucci F, Murru R, Guarini A, Musuraca G, Mineo G, Vincelli I, Arcari A, Tarantini G, Caparrotti G, Chiarenza A, Levato L, Villa MR, De Paolis MR, Zinzani PL, Polliack A, Morabito F. Gentile M, et al. Among authors: herishanu y. Eur J Cancer. 2016 Jun;60:154-65. doi: 10.1016/j.ejca.2016.03.069. Epub 2016 Apr 27. Eur J Cancer. 2016. PMID: 27127905
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Joffe E, Goldschmidt N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, Shvidel L, Greenbaum U, Aviv A, Tadmor T, Braester A, Arad A, Polliack A, Herishanu Y; Israeli CLL Study Group. Joffe E, et al. Among authors: herishanu y. Eur J Haematol. 2018 Sep;101(3):399-406. doi: 10.1111/ejh.13129. Epub 2018 Aug 3. Eur J Haematol. 2018. PMID: 29949186
Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel.
Inbar M, Herishanu Y, Goldschmidt N, Bairey O, Yuklea M, Shvidel L, Fineman R, Aviv A, Ruchlemer R, Braester A, Najib D, Rouvio O, Shaulov A, Greenbaum U, Polliack A, Tadmor T. Inbar M, et al. Among authors: herishanu y. Anticancer Res. 2018 Nov;38(11):6423-6429. doi: 10.21873/anticanres.13003. Anticancer Res. 2018. PMID: 30396967
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y, Tadmor T, Braester A, Bairey O, Aviv A, Rahimi-Levene N, Fineman R, Levi I, Yuklea M, Ruchlemer R, Shvidel L, Polliack A. Herishanu Y, et al. Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12. Hematol Oncol. 2019. PMID: 30756414 Clinical Trial.
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
Tadmor T, Levy I, Herishanu Y, Goldschmidt N, Bairey O, Yuklea M, Shvidel L, Fineman R, Aviv A, Ruchlemer R, Braester A, Dally N, Rouvio O, Shaulov A, Greenbaum U, Inbar M, Polliack A. Tadmor T, et al. Among authors: herishanu y. Leuk Res. 2019 Jul;82:24-28. doi: 10.1016/j.leukres.2019.05.006. Epub 2019 May 19. Leuk Res. 2019. PMID: 31152919
247 results